Tourette Syndrome Clinical Trial
— ORBITOfficial title:
Therapist-guided, Parent-assisted Remote Digital Behavioural Intervention for Tics in Children and Adolescents With Tourette Syndrome: an Internal Pilot Study and Single-blind Randomised Controlled Trial
NCT number | NCT03483493 |
Other study ID # | Hollis201117 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 7, 2018 |
Est. completion date | April 12, 2021 |
Verified date | September 2021 |
Source | Nottinghamshire Healthcare NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Online Remote Behavioural Intervention for Tics (ORBIT). Primary objective: to evaluate the clinical effectiveness of BiP Tic, a therapist-guided, parent-assisted, internet-based behavioural therapy intervention for tics in young people, compared with usual care plus online education. Secondary objectives include 1) optimising the design of the intervention, 2) undertaking an internal pilot, 3) evaluating cost effectiveness and 4) longer term impact, and 5) identifying barriers to implementation.
Status | Completed |
Enrollment | 224 |
Est. completion date | April 12, 2021 |
Est. primary completion date | February 18, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 9 Years to 17 Years |
Eligibility | Inclusion Criteria: 1. Aged 9 to 17: patient confirmed through screening. 2. Suspected or confirmed Tourette syndrome/ chronic tic disorder: - Including Moderate/severe tics: Score >15 on the Yale Global Tic Severity Scale (YGTSS) Total Tic Severity Score (TTSS); TTSS score>10 if motor or vocal tics only: researcher confirms at screening appointment 3. Competent to provide written, informed consent (parental consent for child aged <16): researcher confirms at screening appointment. 4. Broadband internet access and regular PC/ laptop/Mac user, with mobile phone SMS: patient confirmed through screening. Exclusion Criteria: 1. Previous structured behavioural intervention for tics e.g. HRT/CBIT or exposure and response prevention within last 12 months: Patient confirmed through screening. 2. Change to medication for tics (start or stop tic medication) within the previous 2 months: Patient confirmed through screening and subsequent medication/interventions commenced throughout out the trial are recorded at each time point for analysis. 3. Diagnoses of alcohol/substance dependence, psychosis, suicidality, or anorexia nervosa: Confirmed through parent DAWBA. DAWBAs that score people as being likely to have these conditions will be second reviewed by the CI (who is a medical expert) to ascertain that they should definitely be excluded from the trial. If the child is considered at immediate risk of suicide, the research team will inform the GP or usual treating clinician. 4. Moderate/severe intellectual disability: Confirmed through qualitative judgement of the assessor at the telephone screen (and confirmed at baseline through CAIDS-Q) through questions relating to type of school the child attends and previous diagnoses. 5. Immediate risk to self or others: Confirmed through screening questions and DAWBA. The participants GP will be informed of this. 6. Parent or child not able to speak or read/write English: Patient confirmed through screening by the assessor. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Nottinghamshire Healthcare NHS Foundation Trust | Nottingham |
Lead Sponsor | Collaborator |
---|---|
Nottinghamshire Healthcare NHS Trust | Great Ormond Street Hospital for Children NHS Foundation Trust, Karolinska Institutet, NIHR MindTech MedTech Co-operative, University College, London, University of Nottingham |
United Kingdom,
Hollis C, Hall CL, Jones R, Marston L, Novere ML, Hunter R, Brown BJ, Sanderson C, Andrén P, Bennett SD, Chamberlain LR, Davies EB, Evans A, Kouzoupi N, McKenzie C, Heyman I, Khan K, Kilgariff J, Glazebrook C, Mataix-Cols D, Murphy T, Serlachius E, Murray — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | To assess the process evaluation of the interventions qualitative interviews will be conducted | A sub-sample of participants will be as asked to participate in qualitative interviews as part of a process evaluation. | 3months | |
Primary | Assessing change in tics in participants using the Yale Global Tic Severity Scale - Total Tic score | Investigator administered semi structured symptom checklist of 46 tic disorder symptoms. The Total Tic Score is derived by adding the Total Motor Tic Score and the Total Phonic Tic Score | Baseline, 3, 6, 12 and 18 months | |
Secondary | Assessing change in tics in participants using the Parent Tic Questionnaire | Self administered questionnaire to collect the number, frequency and intensity of 14 common motor and 14 common vocal tics | Baseline, 5wks, 3mths, 6mths, 12mths & 18 months | |
Secondary | Assessing change in symptom severity/improvement in participants using the Clinical Global Impressions Scale. | Clinician determined measure that summarises the patient's history, symptoms, behaviours and psychosocial circumstances | 3, 6, 12 & 18 months | |
Secondary | Assessing change in tic impairment in participants using the Yale Global Tic Severity Scale Impairment Scale (assessing change) | This forms part of the YGTSS but focuses on distress and impairment experienced in the individuals life | Baseline, 3, 6, 12 & 18 months | |
Secondary | Assessing change in global functioning in participants using the Children's Global Assessment Scale | A measure of psychiatric disturbance integrating psychological, social and academic functioning | Baseline, 3, 6, 12 & 18 months | |
Secondary | Assessing change in general functioning in participants using the Strengths and Difficulties Questionnaire | Self-report, parent completed questionnaire measuring behavioural and emotional difficulties in children. The baseline SDQ is completed as part of a screening tool "DAWBA". | Baseline, 3, 6, 12 & 18 months | |
Secondary | Assessing change in mood in participants using the Mood and Feelings Questionnaire | Child completed, self-report questionnaire collecting information on depressive symptoms | Baseline, 1, 3, 6, 12 & 18 months | |
Secondary | Assessing change in anxiety in participants using the Spence Child Anxiety Scale | Self-report child completed questionnaire evaluating symptoms of separation anxiety, social phobia, obsessive-compulsive disorder, pain, agoraphobia, generalised anxiety and fear of physical injury | Baseline, 3, 6, 12 & 18 months | |
Secondary | Assessing change in quality of life in participants using the Child Health Utility 9D | Self-report parent and child completed quality of life measure | Baseline, 3, 6,12,18 months | |
Secondary | Assessing change in tic-related quality of life in participants using the Child and Adolescent Gilles de la Tourette Syndrome | A disease specific measure of health related quality of life for children and adolescents with Tourette Syndrome. There are two version, one for children aged 6-12 years and a second for young people aged 3-8 years | Baseline, 3, 6, 12 & 18 months | |
Secondary | Assessing participants change in use of services using the Modified Client Service Receipt Inventory | A questionnaire to collect information on services received, service related issues, school attendance and family income | Baseline, 3, 6, 12 & 18 months | |
Secondary | Assessing change in side effects in participants using the Adverse events/side effects | A 17 item scale of common side effects | Baseline, 1, 3, 6, 12 & 18 months | |
Secondary | Assessing participants perception of treatment credibility using a specifically created 'treatment credibility' questionnaire | A two item questionnaire to assess how well the treatment suits children, according to the perception of the 1) parent/carer and 2) child/young person | 3 weeks | |
Secondary | Assessing participants perception of treatment satisfaction using a specifically created 'treatment satisfaction' questionnaire | A 7 item scale questionnaire developed for the study to assess treatment satisfaction from the perception of the 1) parent/carer and 2) child/young person | 3 months | |
Secondary | Assessing participants perception of their need for further treatment using a specifically created 'Need for further treatment' questionnaire | A single item questionnaire asking if the child or young person requires more treatment for their tics from the perception of the 1) parent/carer and 2) child/young | 3 months | |
Secondary | Assessing participants change of use of other medication/interventions using a specifically created 'Concomitant interventions' questionnaire | Assessment of any other treatment or interventions the child or young person is accessing during the study | Baseline, 3, 6, 12 & 18 months | |
Secondary | Describing sample characteristics using Development and Wellbeing Assessment (DAWBA) at screening/baseline | The DAWBA is a package of interviews and questionnaires completed by parents and teachers and designed to generate ICD-10 and DSM-IV / DSM-5 psychiatric diagnoses for children and young people. | Screening/Baseline | |
Secondary | Determining presence of an intellectual disability at screening/baseline using the Child and Adolescent Intellectual Disability Screening Questionnaire (CAIDS-Q) | A 7-item questionnaire to determine the presence of intellectual disability at screening/baseline, completed by the parent/ | Screening/Baseline | |
Secondary | Understanding the characteristics of the sample a specifically created demographics questionnaire at screening/baseline | Parent completed questionnaire asking about the child's age, gender, ethnicity, parental education/ occupation, list of the child's current diagnoses and interventions (including medications) and GP and school details. | Screening/Baseline | |
Secondary | Determining the for presence of Autism Spectrum Disorder using the Social Communication Questionnaire (SCQ) at screening/baseline | A 40 item, parent-report questionnaire asking about characteristic autistic behaviour at the age of 4 to 5 years and currently. | Screening/Baseline | |
Secondary | Assessing Premonitory urges for tics using the Premonitory Urge for Tics Scale (PUTS) at screening/baseline | A self-report instrument specifically designed to measure the current frequency of different types of premonitory urges in patients with tic disorders | Screening/Baseline | |
Secondary | Assessing ADHD symptoms using the Swanson, Nolan, and Pelham Rating Scale (SNAP-IV) at screening/baseline | A parent completed 26-item behavioural rating scale that employs the core symptoms of ADHD and oppositional defiance disorder (ODD) as defined by the Diagnostic and Statistical Manual of Mental Disorders. | Screening/Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04851678 -
Longitudinal Impact of Stressors in Adults With Tourette Syndrome
|
||
Completed |
NCT02605902 -
Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders
|
N/A | |
Completed |
NCT04007913 -
Incorporating teleCBIT Into a Hospital-Based Tic Program
|
N/A | |
Completed |
NCT02900144 -
Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)
|
N/A | |
Completed |
NCT02216474 -
Brain Stimulation in Movement Disorders
|
N/A | |
Completed |
NCT02256475 -
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
|
Phase 1 | |
Completed |
NCT01329198 -
Brain Stimulation for the Treatment of Tourette Syndrome
|
N/A | |
Terminated |
NCT00952601 -
Pilot Study of the Modified Atkins Diet for Tourette Syndrome
|
Phase 1 | |
Enrolling by invitation |
NCT00355927 -
Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.
|
N/A | |
Completed |
NCT00206323 -
A Randomized, Placebo-controlled, Tourette Syndrome Study.
|
Phase 3 | |
Completed |
NCT00004376 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder
|
Phase 3 | |
Completed |
NCT04498364 -
Extinction Learning in Adults With Tourette Syndrome
|
N/A | |
Completed |
NCT00755339 -
Role of the Sensory Experience in Generating Motor Tics in Tourette Syndrome
|
||
Completed |
NCT03325010 -
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06081348 -
Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
|
Phase 2 | |
Completed |
NCT01719523 -
Open-Trial of EPI-743 for Adults With Tourette Syndrome
|
Phase 1 | |
Completed |
NCT01702077 -
Neurofeedback for Tourette Syndrome
|
N/A | |
Completed |
NCT00231985 -
Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder
|
Phase 2 | |
Completed |
NCT00206336 -
An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
|
Phase 3 | |
Terminated |
NCT03732534 -
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
|
Phase 2 |